We previously reported that cardiac late INa is increased in patients with AS with a HFpEF‐like phenotype and that late INa can be inhibited in human cardiomyocytes by limiting CaMKII activity with empagliflozin9 or by direct inhibition of late INa with ranolazine.10 The gene discussed is CAMK2G; the disease is aortic stenosis.